The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine

PurposeTo retrospectively and comparatively evaluate the improvement of the efficacy and safety on the addition of 252Cf neutron intracavitary brachytherapy (ICBT), individualized or individualized with intrarectal peritumoral injection of amifostine (IPIA) to external-beam radiotherapy (EBRT) or co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yanli Xiong, Li Shao, Jia Liu, Qian Zhou, Chongyi Li, Maojun Liao, Lei Zhang, Xiaoyan Dai, Mengxia Li, Xin Lei
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	rectal adenocarcinoma radiotherapy 252Cf neutron brachytherapy sphincter preservation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d091d478b26c4be785f2c505342103a9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d091d478b26c4be785f2c505342103a9
record_format	dspace
spelling	oai:doaj.org-article:d091d478b26c4be785f2c505342103a92021-11-18T04:46:39ZThe Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine2234-943X10.3389/fonc.2021.758698https://doaj.org/article/d091d478b26c4be785f2c505342103a92021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.758698/fullhttps://doaj.org/toc/2234-943XPurposeTo retrospectively and comparatively evaluate the improvement of the efficacy and safety on the addition of 252Cf neutron intracavitary brachytherapy (ICBT), individualized or individualized with intrarectal peritumoral injection of amifostine (IPIA) to external-beam radiotherapy (EBRT) or concurrent chemo-EBRT in 314 patients with T2N0-1 or T3N0-1 low-lying rectal adenocarcinoma.MethodsPhase I: from 2009 to 2011, 157 patients were treated with additional 252Cf neutron ICBT for four fixed fractions with a total dose of 40–45 Gy-eq during the EBRT. Phase II: from 2011 to 2013, 75 patients were treated with individualized neutron ICBT delivered for two to five fractions with a total dose of 26–45 Gy-eq according to the response of tumor after concurrent chemo-EBRT. Phase III: from 2013 to 2014, 82 patients were treated with individualized ICBT protected by pretreatment IPIA.ResultsThe 4-year local control rates for the entire T2 and T3 patients were 69.4, 72.0, and 79.3%, while the 4-year overall survival rates were 63.1, 54.7, and 72.0% (P=0.08), and the 4-year disease-free survival rates were 55.4, 52.0, and 69.5% (P=0.053) in Phases I, II, and III, respectively. The late complication (LAC, ≥G2) rates were 33.8, 26.7, and 15.9%, respectively (P=0.012), and the serious LAC (≥G3) rates were 4.5, 4.2, and 0%, respectively, in Phases I, II, and III.ConclusionConcurrent chemo-EBRT combined with individualized 252Cf neutron ICBT protected by IPIA shows promising efficacy and safety in treating low-lying T2 and T3 rectal adenocarcinoma patients without surgery opportunity or willing.Yanli XiongLi ShaoJia LiuQian ZhouChongyi LiMaojun LiaoLei ZhangXiaoyan DaiMengxia LiXin LeiXin LeiFrontiers Media S.A.articlerectal adenocarcinomaradiotherapy252Cf neutronbrachytherapysphincter preservationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rectal adenocarcinoma radiotherapy 252Cf neutron brachytherapy sphincter preservation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	rectal adenocarcinoma radiotherapy 252Cf neutron brachytherapy sphincter preservation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yanli Xiong Li Shao Jia Liu Qian Zhou Chongyi Li Maojun Liao Lei Zhang Xiaoyan Dai Mengxia Li Xin Lei Xin Lei The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine
description	PurposeTo retrospectively and comparatively evaluate the improvement of the efficacy and safety on the addition of 252Cf neutron intracavitary brachytherapy (ICBT), individualized or individualized with intrarectal peritumoral injection of amifostine (IPIA) to external-beam radiotherapy (EBRT) or concurrent chemo-EBRT in 314 patients with T2N0-1 or T3N0-1 low-lying rectal adenocarcinoma.MethodsPhase I: from 2009 to 2011, 157 patients were treated with additional 252Cf neutron ICBT for four fixed fractions with a total dose of 40–45 Gy-eq during the EBRT. Phase II: from 2011 to 2013, 75 patients were treated with individualized neutron ICBT delivered for two to five fractions with a total dose of 26–45 Gy-eq according to the response of tumor after concurrent chemo-EBRT. Phase III: from 2013 to 2014, 82 patients were treated with individualized ICBT protected by pretreatment IPIA.ResultsThe 4-year local control rates for the entire T2 and T3 patients were 69.4, 72.0, and 79.3%, while the 4-year overall survival rates were 63.1, 54.7, and 72.0% (P=0.08), and the 4-year disease-free survival rates were 55.4, 52.0, and 69.5% (P=0.053) in Phases I, II, and III, respectively. The late complication (LAC, ≥G2) rates were 33.8, 26.7, and 15.9%, respectively (P=0.012), and the serious LAC (≥G3) rates were 4.5, 4.2, and 0%, respectively, in Phases I, II, and III.ConclusionConcurrent chemo-EBRT combined with individualized 252Cf neutron ICBT protected by IPIA shows promising efficacy and safety in treating low-lying T2 and T3 rectal adenocarcinoma patients without surgery opportunity or willing.
format	article
author	Yanli Xiong Li Shao Jia Liu Qian Zhou Chongyi Li Maojun Liao Lei Zhang Xiaoyan Dai Mengxia Li Xin Lei Xin Lei
author_facet	Yanli Xiong Li Shao Jia Liu Qian Zhou Chongyi Li Maojun Liao Lei Zhang Xiaoyan Dai Mengxia Li Xin Lei Xin Lei
author_sort	Yanli Xiong
title	The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine
title_short	The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine
title_full	The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine
title_fullStr	The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine
title_full_unstemmed	The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine
title_sort	evolving strategy of californium-252 neutron intracavitary brachytherapy in treating patients with low-lying t2 or t3 rectal adenocarcinoma: from fixed to individualized regime with intrarectal peritumoral injection of amifostine
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/d091d478b26c4be785f2c505342103a9
work_keys_str_mv	AT yanlixiong theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT lishao theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT jialiu theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT qianzhou theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT chongyili theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT maojunliao theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT leizhang theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT xiaoyandai theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT mengxiali theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT xinlei theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT xinlei theevolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT yanlixiong evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT lishao evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT jialiu evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT qianzhou evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT chongyili evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT maojunliao evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT leizhang evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT xiaoyandai evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT mengxiali evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT xinlei evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine AT xinlei evolvingstrategyofcalifornium252neutronintracavitarybrachytherapyintreatingpatientswithlowlyingt2ort3rectaladenocarcinomafromfixedtoindividualizedregimewithintrarectalperitumoralinjectionofamifostine
_version_	1718425068317442048

The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine

Ejemplares similares